Studies how the liver processes fat and sugar in fatty liver disease
Compares liver metabolism in people with mild or advanced fatty liver disease and healthy adults.
Plain-language title generated from the registry record
Registry title: Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
Key facts
- Where
- Helsinki, FinlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06942312, who can take part
Where in Finland
- Helsinki Central University HospitalHelsinki, FinlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Helsinki University Central Hospital
- Trial code
- NCT06942312
- Record updated
- 24 April 2025
- Original description
The goal of this observational, cross-sectional, case-control clinical study is to investigate the metabolic adaptations underlying the progression of nonalcoholic fatty liver disease (NAFLD), and to test the hypothesis that hepatic mitochondrial reductive stress contributes to progression of NAFLD.Read full original descriptionShow less
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
The goal of this observational, cross-sectional, case-control clinical study is to investigate the metabolic adaptations underlying the progression of nonalcoholic fatty liver disease (NAFLD), and to test the hypothesis that hepatic mitochondrial reductive stress contributes to progression of NAFLD.
The main question it aims to answer is:
Do patients with advanced NAFLD compared to patients with mild NAFLD and healthy controls have increased hepatic mitochondrial reductive stress as determined by the ketoisocaproate breath test and by plasma beta-hydroxybutyrate to acetoacetate ratio (b-OHB/AcAc)?
The following inclusion/ exclusion criteria will be employed:; Participants must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent; Subject must be likely to be available to complete all protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge; Participants must be aged between 18-75 years; Participants are not allowed to have alcohol consumption of 350 g/week or more in women and 420 g/week or more in men; Participants are not allowed to have history of liver disease other than NAFLD as judged by history and physical examination and standard laboratory tests; Participants are not allowed to have claustrophobia or metal implants to allow magnetic resonance studies; Participants are not allowed to be pregnant or lactating; No known or anticipated difficulties in cannulation of peripheral veins; No history or evidence of any other clinically significant disorder, condition or disease other than those outlined above that, in the opinion of the investigator may compromise the ability of the subject to give written informed consent, would pose a risk to subject safety, or interfere with the study evaluation, procedures or completion.